Kornimate/medical-research-clean huggingface dataset:
evaluating use of microwave technology to differentiate hemorrhagic stroke from infarction in the acute phase

Conditions: Stroke

Summary: this is a prospective, open, multicentre trial that will enrol patients with clinical signs of stroke in the acute phase admitted for ct scan. follow-up microwave measurements will be performed after the acute phase. the study assesses the diagnostic capability and safety of strokefinder md100.

this is a prospective, open, multicentre trial that will enrol patients with clinical signs of stroke in the acute phase admitted for ct scan. the investigator will assess and control the inclusion/exclusion criteria. if the patient is confirmed to be suitable for the trial, the patient is asked to give oral informed consent. if the answer is affirmative the microwave measurement will be performed. the procedure will take less than five minutes (the duration of the actual measurement procedure is 1.5 minutes) and will not interfere with the patient's standard of care during the hospital stay. written informed consent is acquired by the investigator, as soon as possible after the acute phase of care is completed. follow-up microwave measurements will be performed after the acute phase. the measurement data will be evaluated for the presence of signal artifacts. the diagnostic ability of the device will be evaluated using a leave-one-out cross validation (loocv) method with the ct diagnosis as ground truth. safety will be evaluated throughout the trial, and a safety follow-up will be performed by the investigator 24 hours after the last microwave measurement. no further follow-up of patients is planned.

Eligibility criteria:
inclusion criteria: * patient should be ≥ 18 years of age * patient has clinical signs of stroke * patient/next of kin confirms orally that the patient wants to participate in the trial (during acute phase) * signed informed consent form (after acute phase) exclusion criteria: * pregnant or nursing woman * fertile woman where pregnancy cannot be excluded * patient diagnosed with a condition associated with risk of poor protocol compliance * the diagnostic procedure is deemed to interfere with the standard of care * any other condition or symptoms preventing the patient from entering the study, according to the investigator´s judgment * any patient that according to the declaration of helsinki is deemed unsuitable for study enrolment
canadian anticoagulant percutaneous coronary intervention registry

Conditions: Coronary Artery Disease

Summary: advances in mechanical intervention (pci) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease. however, the large diversity of approaches to anticoagulation during pci introduces gaps in knowledge regarding management of cardiac patients. as such, we have initiated a national pci registry to elucidate anticoagulant choice, dosing strategies, case selection dynamics, and clinical outcomes in the canadian health care environment.


Eligibility criteria:
inclusion criteria: 1. 18 or more years of age. 2. undergoing pci during treatment with lmwh 3. provision of written and informed consent exclusion criteria: 1. language, medical, or psychiatric barriers that preclude understanding of informed consent process. 2. patients in which the site investigator is unable to comply with completion of study documentation following pci, i.e. patients with planned transfer to another hospital not participating in the registry. 3. enrollment in a clinical trial involving another anticoagulant agent.

Keywords: coronary artery disease percutaneous coronary intervention anticoagulation
salvage hdr for locally recurrent prostate cancer

Conditions: Prostate Cancer

Summary: the study offers focal salvage brachytherapy for prostate cancer patients with a local recurrence after primary defintive radiotherapy

the aim of this study is to examine the efficacy and toxicity of focal salvage high dose rate brachytherapy (hdr bt) for patients with locally recurrent prostate cancer after definitive external beam radiotherapy. furthermore, the investigators want to assess, whether it is feasible to perform salvage hdr bt as a focal treatment based on multiparametric (mp) pelvine mri and psma pet/ct.

Eligibility criteria:
inclusion criteria: * man ≥ 18 years, who had definitive ebrt or bt for prostate cancer t1-3b, n0-1, m0 * ≥ 2 years since the end of primary radiotherapy * psa recurrence phoenix criteria (nadir + 2) * no evidence of regional lymph nodes or distant metastases on psma pet/ct * mri guided biopsy-proven local recurrence of adenocarcinoma in the prostate gland or seminal vesicles * gtv identifiable on mpmri * no current endocrine therapy * plasma testosterone ≥1.75 nm/l * psa doubling time ≥ 6 months and ≤ 24 months * performance status 0-1 * dan pss score ≤ 20 * maximal urinary flow ≥ 10 ml/s * life expectancy \> 5 years * psa ≤ 10 ug/l at recurrence exclusion criteria: * pubic arc interference or major calcifications within the prostate gland. * contraindication for spinal or general anaesthesia. * conditions indicating that the patient cannot go through the radiation therapy or follow-up, or a condition where the treating oncologist thinks the patient should not participate in the trial, for example due to language problems. * inflammatory bowel disease * contraindications to 3t mri * egfr \< 30 ml/min * ≥ gr 3 urinary toxicity at baseline as assessed by ctcae 4
the neurobiology of expectancy and pain perception

Conditions: Pain

Summary: this study will use using fmri (functional magnetic resonance imaging) to elucidate how contextual learning/expectation relieves or aggravates pain experience in the same cohort of subjects and the same study session.


Eligibility criteria:
inclusion criteria: * a) healthy male and female adults aged 21-50 * b) no contraindications to fmri scanning * c) right handed exclusion criteria: * a) current or past history of major medical, neurological, or psychiatric illness * b) pregnancy or breast feeding, menopause, and irregular menstrual cycles (length of cycle must be within 26 to 32 days) * c) claustrophobia * d) history of head trauma * e) history of impaired elimination * f) instability of responses to experimental pain (see study procedures section) * g) use of psychotropic drugs, hormone treatments (including hormonal birth control) within 1 year * h) non-fluent speaker of english
study of stm-416p administered to patients undergoing radical prostatectomy

Conditions: Prostate Cancer

Summary: a study of stm-416p administered intraoperatively to patients undergoing radical prostatectomy

a phase 1 dose escalation study of stm-416p administered intraoperatively to patients undergoing radical prostatectomy

Eligibility criteria:
inclusion criteria: 1. males aged 18 years or older at time of informed consent. 2. have a histologically confirmed diagnosis of prostate cancer, and are scheduled to undergo radical prostatectomy within 28 days of screening. 3. grade group 2-5. 4. eastern cooperative oncology group (ecog) performance status ≤2 at screening. 5. have adequate organ and bone marrow function at screening. 6. able to understand and be willing to sign an institutional review board/ethics committee-approved written informed consent document exclusion criteria: 1. have an invasive malignancy, other than the disease under study. 2. anticipated to require the use of a drain after radical prostatectomy. 3. received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days. 4. history of allergic reactions attributed to compounds of similar chemical or biologic composition as those used in the stm-416p formulation including poloxamer 407 and sodium hyaluronate. 5. history of allogeneic organ transplant. 6. history of primary immunodeficiency. 7. qtc interval \>470 msec at screening.

Keywords: intraoperative dose escalation open-label stm-416 resiquimod toll-like receptor 7/8 radical prostatectomy robotic prostatectomy immunotherapy stm-416p psa r848 hydrogel
feasibility of omega-3 supplementation for children with language impairments

Conditions: Language Impairment

Summary: the primary objective of this study is to obtain preliminary (pilot) data regarding the feasibility of using dietary omega-3 supplementation in children with significant delays in language skills; a related secondary objective is to compare adherence to a dosage schedule of two easy-to-take formulations. a tertiary objective of this study is to collect preliminary (pilot) data pre- and post-supplementation to identify potential improvement of skills in a specific area of language development.

hypothesis hypothesis 1: children with early developmental impairment in language will successfully take daily omega-3 fatty acid supplementation for a well-defined period of time (3 months); hypothesis 2: children with early developmental impairment will better adhere to administration of a small quantity of slightly fishy-tasting oil than to a large quantity of sweet-tasting paste; hypothesis 3: a 3 month period of daily omega-3 supplementation will produce some improvement in fast-mapping language skills (a dynamic vocabulary learning skill that has been shown to rapidly improve after exposure to beneficial intervention).

Eligibility criteria:
inclusion criteria: * children in the chronological age range of 24 to 42 months at the time of initial assessment * diagnosis of expressive, receptive or mixed language impairment (li) by a certified speech-language pathologist (s-lp) * ability to take daily omega-3 supplementation (with caregiver assistance) exclusion criteria: * children with any organic disease processes or genetic syndromes, or known developmental disorders such as autism that may present with language impairment * children with hearing impairment * children who take any non-standard dietary supplements (i.e., apart from multi-vitamins), particularly any omega-3 fa, prior to starting the study * children whose parents do not have an adequate understanding of english or french

Keywords: language fatty acids nutrition developmental delay
mind body program for fear of recurrence

Conditions: Cancer Survivors

Summary: this is a pilot feasibility study of a group-based, mind body intervention for managing stress and fear of recurrence and promoting resiliency among adult cancer survivors.


Eligibility criteria:
inclusion criteria: 1. patients must have a history of breast, lung, colorectal, hematologic, prostate, melanoma, or gynecological cancer (by medical record and/or self-report) 2. completion of primary cancer treatment (radiation, surgery, and/or chemotherapy) between 3 to 30 months ago 3. ages 18 and older (by medical record and/or self-report) exclusion criteria: 1. self-reported inability to speak and write in english 2. concurrent participation in weekly, group-based psychosocial or mind-body programs 3. serious mental illness (by medical record and/or self-report) as defined by history of suicidality, psychosis, and/or psychiatric hospitalization in the past year. 4. inability to travel to necessary study visits 5. no e-mail address to access online assessments
exploring the acute and dynamic relationships between movement and pain in older adults with musculoskeletal pain

Conditions: Older People; Pain

Summary: the purpose of this research study is to evaluate the effect of brief bouts of intermittent walking on bodily pain, pain during movement, and how the body adapts to musculoskeletal pain in older adults.

the purpose of this study is to determine whether exposure to acute sitting compared to sitting interrupted with brief bouts of light intensity walking exerts short term effects on resting pain, endogenous pain modulation measured via quantitative sensory testing (qst), and movement-evoked pain (mep) in older adults. participants will be asked to complete two study sessions, with the first study session lasting 3 hours and the second study session lasting 2.5 hours. all sessions will take place in the national institute of sport fitness, where the physical activity and pain laboratory is located. the first session will include the following procedures in the following order: informed consent process, healthy history for screening purposes, quantitative sensory testing (qst), 6-minute walk test, completion of questionnaires, qst, experimental conditions of either 1 hour of sitting or 1 hour of sitting with bouts of light intensity walking, qst, and the 30-second chair stand test. session 2 will take place at least 7 days after session 1 and will be identical except for the informed consent and screening will be replaced by questionnaires and the experimental condition will consist of the one not performed in session 1. participants will be asked to take their medications at the same time prior to each study visit and we will assess medications taken the day of each visit prior to the visit.

Eligibility criteria:
inclusion criteria: * community-dwelling men and women * answer yes to the following question: have you experienced any musculoskeletal pain (pain affecting joints, bones, ligaments, tendons or muscles) in the past month? exclusion criteria: * cardiovascular issues such as uncontrolled blood pressure over 150/99 mmhg, heart failure, or history of acute myocardial infarction; * angina in the last month (squeezing, pressure, heaviness, tightness, or pain in chest) * serious systemic disease or condition (e.g., severe osteoarthritis, injury) that restricts normal daily activities * neurological disease (e.g., parkinson's disease, multiple sclerosis, epilepsy) * serious psychiatric conditions (schizophrenia, bipolar disorder) or hospitalization within the preceding year for psychiatric illness * known peripheral neuropathy * chronic opioid use (defined as ≥ 90 days) * unable to walk for 6 minutes without assistive devices session exclusion criteria: • participants will be asked to not participate in vigorous or unaccustomed exercise 48 hours prior to each study session.

Keywords: physical activity movement evoked pain sitting quantitative sensory testing musculoskeletal pain
cold plasma for dental restoration and caries prevention

Conditions: Dental Restoration; Caries

Summary: the main objective of this entire research project is to develop a miniature atmospheric cold plasma brush (m-acpb) for dental clinical applications. the objective of the clinical trial portion of the study is to compare the longevity and durability of dental composite restorations created using the plasma brush, to that of the standard care in dentistry for treating dental cavities, and effects on caries prevention.

the study will be a randomized controlled trial (rct) and be approved by the institute review board of the university of tennessee health science center. the study subjects will be composed of young adults 18-35 years old in order to control effects of age on caries. also the subjects must be caucasian or africa american. young adult patients will be recruited from the uthsc dental clinics.the baseline visit include a dental exam by one of the investigators, standard preventive dental care (e.g cleaning, application of fluoride varnish), anthropometric measurements, oral health interview survey. 100 patients who meet all inclusion and exclusion criteria will be recruited after they sign an informed consent form. these patients will be randomly assigned to 1 of 2 study groups. randomization assignment will be stratified by age and number of teeth with caries. two study groups will be: 1.) plasma treatment group and 2) standard treatment group. for patients in standard treatment group, they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline. for patients in plasma treatment group, they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth. standard preventive treatment and plasma treatment will be repeated on semi-annual (6-month) recall visits. all composite restorations will be placed according to the manufacturer's instruction. only one composite commercially available will be used during the study.

Eligibility criteria:
inclusion criteria: * subject must be caucasian or africa american, 18-35 years old, have written, completed, informed consent forms; * be generally healthy; * be able to participate in the study; * have no diagnosed periodontitis and pericoronitis; * have no active mucosal diseases such as aphthous ulcers and herpetic stomatitis. they must also agree to follow study instructions. the patients must meet the following specific entry criteria: * 1-5 untreated caries and at least one class ii caries. exclusion criteria: * each subject must have no diagnosed diabetes mellitus or any other endocrine diseases; * no diagnosed cardiovascular diseases; * no diagnosed immune-compromised diseases, such as hiv and aids; * no other serious systemic diseases, such as cancer; * no antibiotic therapy in the past 6 months; * no use of non-steroidal anti-inflammatory drugs (nsaids) in the past 3 months; and * no reported use of illicit drugs.

Keywords: dental restoration dental caries tooth cavity
individual and family therapy for children with anxiety disorders

Conditions: Anxiety

Summary: the purpose of this study is to compare three treatments to determine which is most effective in reducing anxiety in children.

children and their parents will complete a comprehensive diagnostic assessment to determine eligibility. the assessment will include an individual diagnostic interview with the child, interviews with the parents, and written observations of the child from family members and teachers. participants will then be randomly assigned to receive individual cognitive behavioral therapy (icbt), family cbt (fcbt), or education/support/attention (esa) for 5 months. children in the icbt group will meet individually with a therapist. in the fcbt and esa treatment groups, children and their parents will meet weekly with a therapist. at the end of treatment and 1 year following treatment completion, families will complete another assessment to determine the effectiveness of each treatment at reducing short- and long-term anxiety symptoms in their children.

Eligibility criteria:
inclusion criteria: * child with dsm-iv criteria for separation anxiety disorder, social phobia, or generalized anxiety disorder exclusion criteria for child participants: * iq less than 80 * current use of anti-anxiety or antidepressant medications * psychotic symptoms * child and/or parent is non-english speaking
efficacy of the myofunctional therapy on oral dysphagia

Conditions: Dysphagia, Oral Phase; Temporomandibular Disorders

Summary: the aim of the study is to analyze the effects of orofacial myofunctional therapy (omt) on oral dysphagia (od) in patients with temporomandibular disorders (tmd).

60 subjects with tmd, according to the research diagnostic criteria, will be included in the study after voluntary consent form will be filled out. subjects will randomly be divided into 3 groups according to the order. home exercise (n=20) will be the group 1, home exercise combined with manual therapy (n=20) will be the group 2, and orofacial myofunctional therapy combined with home exercise and mt treatment (n=20) will be the group 3. group 1 will include educational training program about parafunctional activities of tmd disorders and active exercises for masticatory and neck muscles with 10 repetitions, 3 times a day, and for 10 weeks. group 2 will receive home exercise training program and manual therapy program which is planned to last 30 minutes; will be applied twice a week, for 10 weeks. group 3 will include stretching and strengthening of the tongue muscles, tongue rotation exercises, effortful swallowing, strengthen the hyoidal muscles, which is planned to last 40 minutes, will be applied twice a week, for 10 weeks.

Eligibility criteria:
inclusion criteria: * ages between 18 and 65 years old * patients with diagnosis of group ia, ib, iia and and iii according to the research diagnostic criteria for temporomandibular disorders (rdc/tmd) * having pain ≥ 4 according to the visual analog scale * having score ≥2 points on the eating assessment tool-10 questionnaire * patients who had difficulty in water swallowing tests exclusion criteria: * ages under 18 and over 65 years old * patients with a diagnosis of group ii b,c according to the rdc / tmd evaluation * diagnosis of psychiatric illness * patients with musculoskeletal problems in which systemic specific pathological conditions such as cervical and / or temporomandibular joint (tmj) problem malignancy, fracture, rheumatoid disease is proven * patients who have undergone any surgery related to the cervical and/or tmj * patients with facial paralysis * patients with swallowing difficulties due to the neurological disorders * patients who have received physical therapy associated with tmj in less than 6 months * patients with cognitive deficits * participation rate lower than 80% of the program schedule

Keywords: oral dysphagia temporomandibular disorders quality of life pain
biomarkers in samples from young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer. purpose: this research study is studying biomarkers in samples from young patients with acute myeloid leukemia.

objectives: * determine the extent and prognostic implications of variable s-ship expression and ship gene mutations in pediatric patients with acute myeloid leukemia. * determine the effects of aberrant s-ship expression on the pi3k/akt pathway in these patients via electrochemiluminescence and phosphospecific flow cytometry assays. outline: rna samples are analyzed for variable s-ship expression and are screened for ship mutations. cryopreserved cells (with known high- or low-s-ship expression) are analyzed for the levels of various components of the pi3k/akt pathway via electrochemiluminescence and phosphospecific flow cytometry.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies
fractional co2 laser in the treatment for cesarian scar

Conditions: Cesarian Scar

Summary: fractional co2 laser can improve the cesarian scar


Eligibility criteria:
inclusion criteria: * female receiving cesarean surgery for more than 1 month exclusion criteria: * pregnancy * keloid * photosensitivity * wound * pacemaker * recent retinoid intake

Keywords: cesarian scar fractional co2 laser
community-acquired pneumonia (cap) surveillance

Conditions: Pneumonia

Summary: prospective, non-interventional, multi-center study. 7 investigative centers will involved in china. around 560 cap outpatients or inpatients will be screened until 56 m. pneumoniae isolates collected.


Eligibility criteria:
inclusion criteria: * chinese adult (male or female) ≥18 years old * outpatients or inpatients who suffer from cap exclusion criteria: -

Keywords: pneumonia, surveillance